Grupo Espanol De Oncologia Genitourinaria-Socug

3 trials Academic / non-commercial

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

5 Completed trials

3 Countries active

5 Unique IMPs

100% Results reported

Phase II

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Bladder cancer 1

Top IMPs

ATEZOLIZUMAB 1 CETRELIMAB 1 ERDAFITINIB 1 IPILIMUMAB 1 NIVOLUMAB 1

All trials

3 total

A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monothera… Ended

2024-512573-27-01 Phase II 3 countries CETRELIMAB; ERDAFITINIB
EFFICACY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER Ended

2024-514604-14-00 Phase II 1 country ATEZOLIZUMAB
Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advance… Ended

2024-514293-46-00 Phase II 1 country IPILIMUMAB; NIVOLUMAB

Showing 1–3 of 3 trials

← All sponsors A–Z